For decades, artificial intelligence advanced in careful, mostly linear steps. Researchers built models. Engineers improved performance. Organizations deployed systems to automate specific tasks. Each ...

Success for just one of Recursion's phase 2 programs could enable the stock to double within five years. However, the odds of success for phase 2 candidates aren't good. Risk-averse investors should ...

When Recursion launched in 2013, the fledgling biotech’s goal was to turn machine vision loose on images of cells, at scale, to better understand the biology of disease. Exscientia, founded the year ...

Hi, everybody. My name is Chris Gibson, Co-Founder and CEO of Recursion, and I'm delighted to welcome you to our Earnings Call this morning. We're going to go ahead and get started. Perfect. So, of ...

What if machines could not only learn but also teach themselves to become better with each iteration? This isn’t the plot of a sci-fi movie—it’s the reality unfolding in artificial intelligence ...

Recursion's AI-enabled drug discovery platform continues to evolve, but this is yet to translate into meaningful clinical success. The recent cull of programs has further undermined investor ...